BerGenBio

Investor Presentation • May 4, 2020

BerGenBio ASA – Updated corporated presentation

Bergen, 4 May 2020: Reference is made to the stock exchange notice today 4 May 2020 by BerGenBio ASA ("BerGenBio" or the "Company"), regarding a contemplated private placement.

An updated Corporate Presentation is available at our website under the investor section.

https://www.bergenbio.com/investors/presentations/

For further information, please contact: Richard Godfrey, CEO richard.godfrey@bergenbio.com +47 917 86 304

Rune Skeie, CFO rune.skeie@bergenbio.com +47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab (BGB149) is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

***

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward -looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of BerGenBio and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forwardlooking statements. BerGenBio assumes no responsibility to update forward -looking statements or to adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.